Dianthus TherapeuticsDNTH +4.58%22 Net Current Asset Value is $19.68 as of Mar. 2026, which is 690% above its 10-year median of 2.49. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.91 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 943 Biotechnology companies, Dianthus Therapeutics ranks better than 51.33% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Dianthus Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was $19.68.
The historical rank and industry rank for Dianthus Therapeutics's Net Current Asset Value or its related term are showing as below:
DNTH'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.92 Med: 2.49 Max: 4.79
Current: 4.79
During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Dianthus Therapeutics was 4.79. The lowest was 0.92. And the median was 2.49.
DNTH's Price-to-Net-Current-Asset-Value is ranked better than 51.33% of 943
companies
in the Biotechnology industry
Industry Median: 4.96
vs DNTH: 4.79
Dianthus Therapeutics (NAS:DNTH) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Dianthus Therapeutics Net Current Asset Value Related Terms
Dianthus Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Dianthus Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dianthus Therapeutics Net Current Asset Value Chart
DNTH vs CAI, TNGX, MANE: Net Current Asset Value Comparison
For the Biotechnology subindustry, Dianthus Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dianthus Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Dianthus Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $19.68 mean?
Dianthus Therapeutics (DNTH) has a Net Current Asset Value of $19.68 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Dianthus Therapeutics and its competitors. This is 690% above median its historical median of 2.49. Over the past decade, Dianthus Therapeutics' Net Current Asset Value has ranged from 0.92 to 4.79. According to the industry distribution chart, Dianthus Therapeutics ranks #459 out of 943 companies in the Biotechnology industry, placing it in the top 48.7%.
Is Dianthus Therapeutics' Net Current Asset Value too high?
Dianthus Therapeutics' current Net Current Asset Value of $19.68 is 690% above median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 4.79. The Biotechnology industry median Net Current Asset Value is 4.96. Dianthus Therapeutics' value of $19.68 is 296.8% above this industry median. Based on the distribution chart, Dianthus Therapeutics ranks #459 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Net Current Asset Value compare to CAI and TNGX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #459 out of 943 companies for Net Current Asset Value. This puts Dianthus Therapeutics in the upper half of its industry. The industry median Net Current Asset Value is 4.96. Dianthus Therapeutics' value of $19.68 is 296.8% above this benchmark. Historically, Dianthus Therapeutics' own Net Current Asset Value has ranged from 0.92 to 4.79 over the past decade. While the company's 10-year median is 2.49 vs. the industry median of 4.96, Dianthus Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.96, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dianthus Therapeutics's current Net Current Asset Value of $19.68 is 296.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Dianthus Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dianthus Therapeutics's current Net Current Asset Value is $19.68, which is 690% above median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.91, compared to a current price of $94.34 — trading 3141.9% above its estimated fair value. The current Net Current Asset Value is $19.68, which is 690% above median its 10-year median of 2.49 and 296.8% above the Biotechnology industry median of 4.96. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Net Current Asset Value is $19.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dianthus Therapeutics (DNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued.
The current stock price of $94.34 is trading 3141.9% above its estimated GF Value™ of $2.91.
GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.
Key valuation signals for DNTH:
Net Current Asset Value: $19.68 (690% above median its 10-year median of 2.49)
GF Value™: $2.91 vs. price of $94.34 (3141.9% above fair value)
Industry Position: 296.8% above the Biotechnology median (#459 of 943)
No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score
Get the complete analysis for DNTH
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNTH has been successfully added to your 
